CARACara Therapeutics, Inc.

Nasdaq caratherapeutics.com


$ 0.33 $ -0.01 (-3.32 %)    

Monday, 19-Aug-2024 15:58:22 EDT
QQQ $ 481.15 $ 6.24 (1.31 %)
DIA $ 409.09 $ 2.37 (0.58 %)
SPY $ 559.11 $ 5.30 (0.96 %)
TLT $ 97.90 $ 0.45 (0.46 %)
GLD $ 231.62 $ -0.38 (-0.16 %)
$ 0.3237
$ 0.34 x 100
-- x --
-- - --
$ 0.24 - $ 3.06
351,407
na
17.71M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-06-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-10-2017 12-31-2016 10-K
32 11-04-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-27-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-cara-therapeutics-stock

Cara Therapeutics shares are trading higher by 15% during Thursday's session. The company earlier announced it engaged Pipe...

 cara-therapeutics-reveals-process-of-exploring-and-reviewing-strategic-alternatives

As of March 31, 2024, the Company had approximately $70 million in cash, cash equivalents, and marketable securities.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION